Simulations Plus, Inc.
As contemplated by the SEC under Article 8 of Regulation S-X, the accompanying consolidated financial statements and footnotes have been condensed and therefore do not contain all disclosures required by generally accepted accounting principles.
Results for interim periods are not necessarily indicative of those to be expected for the full year.
Recently, the Company has begun to explore developing software applications for defense and for health care outside of the pharmaceutical industry.
Significant accounting policies for us include revenue recognition, accounting for capitalized computer software development costs, valuation of stock options, and accounting for income taxes.
The standard also provides guidance on the recognition of incremental costs related to obtaining customer contracts.
We adopted ASC Topic 606, effective September 1, 2018, utilizing the modified retrospective method.
The reported results for fiscal year 2019 reflect the application of ASC Topic 606, while the reported results for fiscal year 2018 are not adjusted and continue to be reported under ASC Topic 605.
We generate revenue primarily from the sale of software licenses and providing consulting services to the pharmaceutical industry for drug development.Item 2.
The forward-looking statements contained or incorporated by reference in this document are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”) and are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995.
We are a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents, and are one of only two global companies who provide a wide range of early discovery, preclinical, and clinical consulting services and software.
We generate revenue by delivering relevant, cost-effective software and creative and insightful consulting services.
Pharmaceutical and biotechnology companies use our software programs and scientific consulting services to guide early drug discovery (molecule design and screening), preclinical, and clinical development programs.
Simulations Plus previously acquired Cognigen Corporation (Cognigen) as a wholly owned subsidiary.
Our clinical-pharmacology-based consulting services include pharmacokinetic and pharmacodynamic modeling, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions.
We have also developed software for harnessing cloud-based computing in support of modeling and simulation activities and secure data archiving, and we provide consulting services to improve interdisciplinary collaborations and research and development productivity.
Simulation Plus also acquired DILIsym Services, Inc. (DILIsym) as a wholly owned subsidiary.